In the field of global health, the term “super-bug” has become increasingly common. Although it may sound sensationalist, it describes an alarming reality: the emergence of bacteria that have developed resistance to multiple antibiotic treatments, which seriously complicates their clinical management.
A super-bug is, in microbiological terms, a bacterial strain that has evolved mechanisms to survive several classes of antibiotics. Some are even resistant to so-called “last-resort antibiotics,” critically limiting the available therapeutic options. When a person becomes infected with one of these bacteria, the consequences can be severe: conventional treatments fail, hospital stays become longer, costs rise, and mortality rates increase significantly.
BACTERIAL RESISTANCE AND MECHANISMS
The phenomenon is technically classified into three levels based on the degree of resistance:
-
Multidrug-resistant (MDR)
-
Extensively drug-resistant (XDR)
-
Pandrug-resistant (PDR)
In the last case, no available antibiotic is effective, representing a highest-risk scenario.
Clinically, some of the most concerning strains include:
-
Klebsiella pneumoniae resistant to carbapenems, common in hospital-acquired infections
-
Methicillin-resistant Staphylococcus aureus (MRSA), widely found in skin and respiratory infections
-
Escherichia coli, increasingly resistant to third-generation cephalosporins
-
Neisseria gonorrhoeae, with strains that resist nearly all known treatments
These bacteria not only exhibit resistance but can also transfer their resistance genes to other species through plasmids or other mobile genetic elements, accelerating the spread of the problem across different environments.
The mechanisms behind this resistance are diverse and complex. In some cases, bacteria alter the proteins targeted by antibiotics, rendering them ineffective. In others, they produce enzymes that degrade the drug before it acts, or they modify the permeability of their membranes to block the entry of the compound. Some develop efflux pumps that expel the antibiotic from within, while others form biofilms, which make drug penetration significantly harder.
SLOWING RESISTANCE
For decades, the response to antibiotic resistance was to develop new synthetic antibiotics. However, the pace of innovation has stalled. Major pharmaceutical companies have reduced investment in this area due to low profitability and regulatory hurdles. Meanwhile, bacteria have continued to adapt. This has prompted an urgent search for new solutions from less explored sources—such as the fungal kingdom.
Fungi, which have coexisted and competed with bacteria for millions of years, have evolved a wide range of bioactive compounds as a defense mechanism. Many of these secondary metabolites have unique chemical structures and modes of action distinct from conventional antibiotics, making them a promising source for the development of new antimicrobial therapies.
THE HIFAS BIOLOGICS APPROACH
In this context, at Hifas Biologics, we are working precisely in that direction: researching fungal species from extreme habitats with the goal of identifying compounds capable of halting the advance of resistant bacteria. Our work involves isolating and studying these molecules, evaluating their effectiveness through advanced biotechnology, experimental pharmacology, and computational analysis.
We strongly believe that nature still holds answers yet to be discovered, and that fungi may be key allies in restoring the therapeutic balance lost in the fight against super-bugs.